Shopping Cart 0
Cart Subtotal
AED 0

Syros Pharmaceuticals Inc (SYRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company's pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and SY-1365, a potent and selective small molecule inhibitor of CDK7 that is used to treat patients with transcriptionally driven solid tumors and acute leukemias. Syors provides gene regulation, new medicines development, proprietary drug development platform, and integrated gene control assay technologies. Its gene control platform identifies novel gene control targets linked to genomically defined patient populations, and drugging gene control targets. The company partners with other biopharmaceutical companies to extend the potential of our gene control platform across multiple therapeutic areas and diseases. Syros is headquartered in Cambridge, Massachusetts, the US.

Syros Pharmaceuticals Inc (SYRS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Syros Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Syros Pharma Raises USD10 Million in Venture Financing 13

Syros Pharma Raises USD40 Million in Venture Financing 14

Syros Pharma Raises USD53 Million in Series B Venture Financing 16

Syros Pharma Raises USD 30 Million In Series A Financing 18

LS22 Raises USD1.25 Million in Venture Financing 19

LS22 Raises USD1.3 Million in Venture Financing 20

Partnerships 21

Incyte and Syros Pharma Enter into Agreement 21

Syros Pharma Amends Research Agreement With Multinational Pharmaceutical Company 22

Licensing Agreements 23

Syros Pharma Amends Licensing Agreement with TMRC 23

Syros Pharma Enters into Licensing Agreement with Whitehead Institute 24

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 25

Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 27

Equity Offering 28

Syros Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD46 Million 28

Syros Pharma Raises USD1.2 Million in Private Placement of Shares 30

Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 31

Syros Pharma Plans to Raise Funds through Public Offering of Shares 32

Syros Pharma Raises USD35 Million in Private Placement of Shares 33

Syros Pharma Raises USD57.5 Million in IPO 34

Syros Pharmaceuticals Inc-Key Competitors 36

Syros Pharmaceuticals Inc-Key Employees 37

Syros Pharmaceuticals Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Aug 07, 2018: Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones 39

May 10, 2018: Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones 41

Mar 12, 2018: Syros Announces Fourth Quarter and Full Year 2017 Financial Results 43

Nov 08, 2017: Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones 45

Aug 09, 2017: Syros Reports Second Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones 47

May 15, 2017: Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones 49

Mar 20, 2017: Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones 51

Corporate Communications 53

Mar 12, 2018: Syros Pharmaceuticals Appoints Joseph J. Ferra As Chief Financial Officer 53

Nov 13, 2017: Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer 54

Jun 12, 2017: Syros Appoints Srinivas Akkaraju to Its Board of Directors 55

Jan 30, 2017: Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors 56

Government and Public Interest 57

Feb 27, 2017: Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference 57

Product News 58

Jun 19, 2017: Syros Presents Discovery of Key Genes Controlling the Autoimmune Response in Lupus in Late-Breaking Oral Presentation at FOCIS Meeting 58

03/01/2017: Syros to Present New Data on CDK12/13 Inhibitor program at Upcoming AACR Annual Meeting 59

Other Significant Developments 60

Jan 08, 2018: Syros Announces 2018 Strategic Priorities and Expected Milestones 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Syros Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Syros Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Syros Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Syros Pharma Raises USD10 Million in Venture Financing 13

Syros Pharma Raises USD40 Million in Venture Financing 14

Syros Pharma Raises USD53 Million in Series B Venture Financing 16

Syros Pharma Raises USD 30 Million In Series A Financing 18

LS22 Raises USD1.25 Million in Venture Financing 19

LS22 Raises USD1.3 Million in Venture Financing 20

Incyte and Syros Pharma Enter into Agreement 21

Syros Pharma Amends Research Agreement With Multinational Pharmaceutical Company 22

Syros Pharma Amends Licensing Agreement with TMRC 23

Syros Pharma Enters into Licensing Agreement with Whitehead Institute 24

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 25

Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 27

Syros Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD46 Million 28

Syros Pharma Raises USD1.2 Million in Private Placement of Shares 30

Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 31

Syros Pharma Plans to Raise Funds through Public Offering of Shares 32

Syros Pharma Raises USD35 Million in Private Placement of Shares 33

Syros Pharma Raises USD57.5 Million in IPO 34

Syros Pharmaceuticals Inc, Key Competitors 36

Syros Pharmaceuticals Inc, Key Employees 37

Syros Pharmaceuticals Inc, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Syros Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company's pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and SY-1365, a potent and selective small molecule inhibitor of CDK7 that is used to treat patients with transcriptionally driven solid tumors and acute leukemias. Syors provides gene regulation, new medicines development, proprietary drug development platform, and integrated gene control assay technologies. Its gene control platform identifies novel gene control targets linked to genomically defined patient populations, and drugging gene control targets. The company partners with other biopharmaceutical companies to extend the potential of our gene control platform across multiple therapeutic areas and diseases. Syros is headquartered in Cambridge, Massachusetts, the US.

Syros Pharmaceuticals Inc (SYRS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Syros Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Syros Pharma Raises USD10 Million in Venture Financing 13

Syros Pharma Raises USD40 Million in Venture Financing 14

Syros Pharma Raises USD53 Million in Series B Venture Financing 16

Syros Pharma Raises USD 30 Million In Series A Financing 18

LS22 Raises USD1.25 Million in Venture Financing 19

LS22 Raises USD1.3 Million in Venture Financing 20

Partnerships 21

Incyte and Syros Pharma Enter into Agreement 21

Syros Pharma Amends Research Agreement With Multinational Pharmaceutical Company 22

Licensing Agreements 23

Syros Pharma Amends Licensing Agreement with TMRC 23

Syros Pharma Enters into Licensing Agreement with Whitehead Institute 24

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 25

Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 27

Equity Offering 28

Syros Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD46 Million 28

Syros Pharma Raises USD1.2 Million in Private Placement of Shares 30

Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 31

Syros Pharma Plans to Raise Funds through Public Offering of Shares 32

Syros Pharma Raises USD35 Million in Private Placement of Shares 33

Syros Pharma Raises USD57.5 Million in IPO 34

Syros Pharmaceuticals Inc-Key Competitors 36

Syros Pharmaceuticals Inc-Key Employees 37

Syros Pharmaceuticals Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Financial Announcements 39

Aug 07, 2018: Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones 39

May 10, 2018: Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones 41

Mar 12, 2018: Syros Announces Fourth Quarter and Full Year 2017 Financial Results 43

Nov 08, 2017: Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones 45

Aug 09, 2017: Syros Reports Second Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones 47

May 15, 2017: Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones 49

Mar 20, 2017: Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones 51

Corporate Communications 53

Mar 12, 2018: Syros Pharmaceuticals Appoints Joseph J. Ferra As Chief Financial Officer 53

Nov 13, 2017: Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer 54

Jun 12, 2017: Syros Appoints Srinivas Akkaraju to Its Board of Directors 55

Jan 30, 2017: Syros Appoints Industry Leader Peter Wirth as Chair of Its Board of Directors 56

Government and Public Interest 57

Feb 27, 2017: Syros Reports Discovery of Novel Genomics Based Approach to Stratifying Patients with Acute Myeloid Leukemia at Cold Spring Harbor Conference 57

Product News 58

Jun 19, 2017: Syros Presents Discovery of Key Genes Controlling the Autoimmune Response in Lupus in Late-Breaking Oral Presentation at FOCIS Meeting 58

03/01/2017: Syros to Present New Data on CDK12/13 Inhibitor program at Upcoming AACR Annual Meeting 59

Other Significant Developments 60

Jan 08, 2018: Syros Announces 2018 Strategic Priorities and Expected Milestones 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Syros Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Syros Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Syros Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Syros Pharma Raises USD10 Million in Venture Financing 13

Syros Pharma Raises USD40 Million in Venture Financing 14

Syros Pharma Raises USD53 Million in Series B Venture Financing 16

Syros Pharma Raises USD 30 Million In Series A Financing 18

LS22 Raises USD1.25 Million in Venture Financing 19

LS22 Raises USD1.3 Million in Venture Financing 20

Incyte and Syros Pharma Enter into Agreement 21

Syros Pharma Amends Research Agreement With Multinational Pharmaceutical Company 22

Syros Pharma Amends Licensing Agreement with TMRC 23

Syros Pharma Enters into Licensing Agreement with Whitehead Institute 24

Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 25

Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 27

Syros Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD46 Million 28

Syros Pharma Raises USD1.2 Million in Private Placement of Shares 30

Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 31

Syros Pharma Plans to Raise Funds through Public Offering of Shares 32

Syros Pharma Raises USD35 Million in Private Placement of Shares 33

Syros Pharma Raises USD57.5 Million in IPO 34

Syros Pharmaceuticals Inc, Key Competitors 36

Syros Pharmaceuticals Inc, Key Employees 37

Syros Pharmaceuticals Inc, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Syros Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.